Jenburkt Pharmaceuticals Ltd to Consider Q2 FY27 Results

Jenburkt Pharmaceuticals Ltd will consider its standalone unaudited results for the quarter and half-year ended September 30, 2026, at a board meeting on November 3, 2026, following FY26 sales growth of 11.24% to ₹168.74 crore and a weaker June quarter.

What will Jenburkt Pharmaceuticals consider at its November 3 board meeting?

Jenburkt Pharmaceuticals will consider and approve standalone unaudited financial results for the July-September 2026 quarter, or Q2 FY27, and the half-year ended September 30, 2026. The disclosure to BSE specifies that the company’s board meeting is scheduled for November 3, 2026.

The announcement is a scheduled corporate disclosure rather than a release of financial results. Therefore, the available information does not state Q2 FY27 revenue, profit, margins, expenses, or earnings per share. Investors will have to wait for the board-approved filing to assess the company’s performance during the September quarter.

The meeting follows the company’s Q1 FY27 results for the quarter ended June 2026. In that period, standalone sales declined marginally to ₹35.51 crore from ₹35.53 crore a year earlier. Standalone net profit fell 24.39% year-on-year to ₹5.89 crore from ₹7.79 crore.

The June-quarter figures represented a softer start to FY27 after the company ended FY26 with higher annual sales and profit. The reported decline in quarterly profit was substantially larger than the movement in sales, making operating performance and profitability important points to monitor in the upcoming results.

How did Jenburkt Pharmaceuticals perform in the June 2026 quarter?

Jenburkt Pharmaceuticals reported standalone sales of ₹35.51 crore and net profit of ₹5.89 crore in Q1 FY27, compared with ₹35.53 crore and ₹7.79 crore, respectively, in Q1 FY26. Sales were lower by 0.06% year-on-year, while net profit declined by 24.39%.

Available quarterly data also show that revenue declined from ₹44.63 crore in the March 2026 quarter to about ₹35.5 crore in the June 2026 quarter. Net profit declined from ₹10.85 crore in the March quarter. These sequential comparisons reflect the reported results of two different quarters and do not establish the reasons for the movement.

The June-quarter operating margin was reported at 17.0%. Quarterly EBITDA was ₹5.945 crore, while operating income was ₹5.386 crore, according to the financial information provided. Gross profit for the latest reported quarter was ₹29.19 crore.

The company had earlier closed its trading window from July 1, 2026, for designated persons and insiders. It said the window would reopen 48 hours after the Q1 FY27 standalone unaudited results were made public, in line with the stated compliance process.

What was Jenburkt Pharmaceuticals' financial performance in FY26?

Jenburkt Pharmaceuticals reported FY26 standalone sales of ₹168.74 crore, up 11.24% from ₹151.69 crore in FY25. Standalone net profit rose 8.36% to ₹34.74 crore from ₹32.06 crore in the preceding financial year.

Revenue in FY26 was also reported as ₹1,687.41 million, equivalent to ₹168.74 crore. Gross profit was ₹1,349.57 million, or ₹134.96 crore, and operating income was ₹425.06 million, or ₹42.51 crore. The company reported FY26 earnings per share of ₹78.71, compared with ₹72.65 in FY25.

The FY26 net profit margin was reported at 21%, unchanged from FY25. This annual performance provides the broader reference point for the September-quarter results, particularly because the June quarter recorded a decline in both revenue and net profit against the corresponding period a year earlier.

Jenburkt Pharmaceuticals submitted its FY26 annual report to BSE on August 3, 2026. The filing included audited standalone financial statements, the auditors’ report, directors’ report, and the notice convening the company’s 41st annual general meeting.

Why do the September-quarter results matter for investors?

The Q2 FY27 filing will show whether the June-quarter sales and profit decline persisted, improved, or changed during the following three months. Since the board will also consider half-year results, the disclosure will offer a view of performance for the first six months of FY27 rather than only one quarter.

For investors, the relevant reported indicators will include revenue, net profit, EBITDA, operating margin, earnings per share, and any stated comparison with the prior-year period. The June result showed sales were broadly flat year-on-year while net profit declined, so the September filing will provide the next official set of data on the company’s operating trend.

The results are also relevant to market participants because Jenburkt Pharmaceuticals is listed on BSE under scrip code 524731. However, no share-price movement, management outlook, dividend proposal, or operational guidance is stated in the provided announcement, and these should not be assumed before the official filing.

The company operates in the pharmaceutical sector, where periodic financial disclosures are a key source of information on sales trends and profitability. The available records show FY26 sales growth of 11.24%, followed by a nearly unchanged sales figure in Q1 FY27, placing the next disclosure in the context of two different reporting periods.

What information remains pending from the board meeting?

The pending information includes Jenburkt Pharmaceuticals' standalone Q2 FY27 revenue, profit after tax, operating performance, and half-year financial figures for the period ended September 30, 2026. The source only confirms that these unaudited results are due for consideration by the board on November 3.

The results announcement may also contain the detailed profit and loss account, comparative figures and notes accompanying the standalone financial statements. Until the board-approved results are published, the financial impact of the September quarter has not been disclosed.

Conclusion

Jenburkt Pharmaceuticals enters its November 3 board meeting after reporting growth in FY26 sales and net profit, but a weaker Q1 FY27, in which sales were ₹35.51 crore and net profit was ₹5.89 crore. The scheduled meeting is significant because it will provide the next formal update on quarterly and first-half performance.

Investors should watch for the board-approved standalone Q2 FY27 and half-year results for the period ended September 30, 2026. The disclosed agenda does not provide a target, outlook, or forecast, so the published revenue, profitability and margin figures will be the key new information.